# High-dose ICE With Amifostine

> **NCT00003657** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 24 (actual)

## Conditions studied

- Bladder Cancer
- Brain and Central Nervous System Tumors
- Carcinoma of Unknown Primary
- Extragonadal Germ Cell Tumor
- Head and Neck Cancer
- Kidney Cancer
- Lung Cancer
- Ovarian Cancer
- Sarcoma
- Testicular Germ Cell Tumor
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** Amifostine
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00003657
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** 2000-11
- **Final completion:** 2002-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003657, "High-dose ICE With Amifostine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*